Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):283–290. doi: 10.1054/bjoc.1999.0916

Prostate cancer treated by anti-androgens: is sexual function preserved?

F H Schröder 1, L Collette 1, T M de Reijke 1, P Whelan 1; members of the E. O. R. T. C. Genitourinary Group1,1
PMCID: PMC2363280  PMID: 10646878

Abstract

This paper reports on results of the EORTC protocol 30892, an open, prospective, randomized study of 310 patients with previously untreated metastatic prostate cancer with favourable prognostic factors who were treated by either flutamide (FLU) or cyproterone acetate (CPA) monotherapy. The final analysis with regard to the main end points, time to progression and survival are still pending. Final results related to the evaluation of sexual functioning prior to and under treatment are reported here. Of 310 randomized patients 294 were eligible for evaluation within this side study. The median age was 71 years (range 48–85). Potential risk factors related to age, general health and prostate cancer were evaluated. For evaluation of sexual functions a five-item questionnaire was used which was administered by the investigator. The protocol allowed time dependent observations at 3-monthly follow-up visits. Sexual functioning was dependent on age but not on prostate cancer-related parameters. Sexual functions at entry were similar within the two treatment groups, spontaneous (nightly) erections and sexual activity were seen in 43–51% and 29–35% of cases. Under treatment, sexual functions under FLU and CPA declined slowly with median times of 12.9 and 5.8 months versus 13.7 and 8.9 months respectively for spontaneous erections and sexual activity. Eventually, with an average observation time in excess of 2 years, loss of spontaneous erections and of sexual activity occurred in 80% versus 92% and in 78% versus 88% of men under FLU versus CPA treatment respectively. None of these differences reached statistical significance. Maintenance of potency under treatment with FLU as reported in the literature is not confirmed in this study. However, loss of sexual functions under monotherapy with both antiandrogens is slow and 10–20% of men retain sexual activity after 2–6 years of treatment. This observation can be exploited in new treatment schemes and is likely to lead to improved quality of life. The advantage of FLU in time and total preservation of sexual functions is statistically not significant and must be balanced against the side effects of FLU and other pure antiandrogens, which may exceed those of CPA especially with respect to gynaecomastia. Hepatic toxicity may limit the long-term use of both drugs. © 2000 Cancer Research Campaign

Keywords: prostate cancer, anti-androgens, sexual function

Full Text

The Full Text of this article is available as a PDF (83.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackledge G. R. High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology. 1996 Jan;47(1A):44–53. doi: 10.1016/s0090-4295(96)80008-2. [DOI] [PubMed] [Google Scholar]
  2. Boccon-Gibod L. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Eur Urol. 1998;33(2):159–164. doi: 10.1159/000019548. [DOI] [PubMed] [Google Scholar]
  3. Diokno A. C., Brown M. B., Herzog A. R. Sexual function in the elderly. Arch Intern Med. 1990 Jan;150(1):197–200. [PubMed] [Google Scholar]
  4. Eisenberger M. A., Blumenstein B. A., Crawford E. D., Miller G., McLeod D. G., Loehrer P. J., Wilding G., Sears K., Culkin D. J., Thompson I. M., Jr Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998 Oct 8;339(15):1036–1042. doi: 10.1056/NEJM199810083391504. [DOI] [PubMed] [Google Scholar]
  5. Feldman H. A., Goldstein I., Hatzichristou D. G., Krane R. J., McKinlay J. B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan;151(1):54–61. doi: 10.1016/s0022-5347(17)34871-1. [DOI] [PubMed] [Google Scholar]
  6. Fitzpatrick J. M., Kirby R. S., Krane R. J., Adolfsson J., Newling D. W., Goldstein I. Sexual dysfunction associated with the management of prostate cancer. Eur Urol. 1998;33(6):513–522. doi: 10.1159/000019648. [DOI] [PubMed] [Google Scholar]
  7. Goldenberg S. L., Bruchovsky N., Gleave M. E., Sullivan L. D., Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995 May;45(5):839–845. doi: 10.1016/s0090-4295(99)80092-2. [DOI] [PubMed] [Google Scholar]
  8. Helgason A. R., Arver S., Adolfsson J., Dickman P., Granath F., Steineck G. 'Potency': the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test-retest reliability. Br J Urol. 1998 Jan;81(1):135–141. doi: 10.1046/j.1464-410x.1998.00512.x. [DOI] [PubMed] [Google Scholar]
  9. Jacobi G. H., Altwein J. E., Kurth K. H., Basting R., Hohenfellner R. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol. 1980 Jun;52(3):208–215. doi: 10.1111/j.1464-410x.1980.tb02961.x. [DOI] [PubMed] [Google Scholar]
  10. Lund F., Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol. 1988 Feb;61(2):140–142. doi: 10.1111/j.1464-410x.1988.tb05062.x. [DOI] [PubMed] [Google Scholar]
  11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  12. Morley J. E. Impotence in older men. Hosp Pract (Off Ed) 1988 Apr 15;23(4):139-42, 145-6, 152-3 passim. doi: 10.1080/21548331.1988.11703458. [DOI] [PubMed] [Google Scholar]
  13. Pavone-Macaluso M., de Voogt H. J., Viggiano G., Barasolo E., Lardennois B., de Pauw M., Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol. 1986 Sep;136(3):624–631. doi: 10.1016/s0022-5347(17)44996-2. [DOI] [PubMed] [Google Scholar]
  14. Robinson M. R., Smith P. H., Richards B., Newling D. W., de Pauw M., Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol. 1995;28(4):273–283. [PubMed] [Google Scholar]
  15. Sogani P. C., Vagaiwala M. R., Whitmore W. F., Jr Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer. 1984 Aug 15;54(4):744–750. doi: 10.1002/1097-0142(1984)54:4<744::aid-cncr2820540426>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  16. Stenman U. H., Hakama M., Knekt P., Aromaa A., Teppo L., Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994 Dec 10;344(8937):1594–1598. doi: 10.1016/s0140-6736(94)90405-7. [DOI] [PubMed] [Google Scholar]
  17. de Voogt H. J., Studer U., Schröder F. H., Klijn J. G., de Pauw M., Sylvester R. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol. 1998;33(2):152–158. doi: 10.1159/000019547. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES